Develops drugs for rare diseases like amyotrophic lateral sclerosis and familial chylomicronemia syndrome.
Jun 2026Revenue $874M/yrExpenses $1.47B/yr
No trendCash runway ≈ 3.7 years from Jun 2026
Figures by year
When will Ionis Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $874M and expenses $1.47B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $944M | $1.33B | −$382M |
| Dec 2024 | $705M | $1.18B | −$475M |
| Dec 2023 | $788M | $1.14B | −$354M |
| Dec 2022 | $587M | $998M | −$410M |
| Dec 2021 | $810M | $841M | −$30.2M |
| Dec 2020 | $729M | $901M | −$172M |
| Dec 2019 | $1.12B | $757M | $366M |
| Dec 2018 | $600M | $661M | −$61.4M |
| Dec 2017 | $514M | $483M | $31.0M |
| Dec 2016 | $373M | $393M | −$20.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.